Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17158343 | 0.99 | KCNH3 (0.48) | KCNH3KDM4EMEN1HTTKMT2A | |
| SCHEMBL17158233 | 0.87 | KCNH3 (0.50) | KCNH3MEN1HTTKMT2AMAPT | |
| SCHEMBL15720459 | 0.86 | KCNH3 (0.43) | KCNH3KDM4EMEN1HTTKMT2A | |
| SCHEMBL15719866 | 0.86 | KCNH3 (0.58) | KCNH3KDM4EMEN1HTTKMT2A | |
| SCHEMBL15720500 | 0.86 | KCNH3 (0.58) | KCNH3KDM4EMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL17158342 | 0.86 | KCNH3 (0.52) | KCNH3KDM4EMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL15720208 | 0.85 | KCNH3 (0.45) | KCNH3KDM4EMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL17158228 | 0.85 | KCNH3 (0.61) | KCNH3KDM4EMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL17158317 | 0.85 | KCNH3 (0.61) | KCNH3KDM4EMEN1HTTKMT2A | |
| SCHEMBL15739169 | 0.85 | KCNH3 (0.42) | KCNH3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | claimed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023225177-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2920155-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | KCNH3 662/4885KDM4E 2313/4885MEN1 4603/4885 |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | MTNR1B, TNNC1, PER2 | KCNH3 1980/4885KDM4E 2792/4885MEN1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.